DK0646016T3 - Syntetiske peptider til behandlling af myasthenia gravis - Google Patents

Syntetiske peptider til behandlling af myasthenia gravis

Info

Publication number
DK0646016T3
DK0646016T3 DK93916644T DK93916644T DK0646016T3 DK 0646016 T3 DK0646016 T3 DK 0646016T3 DK 93916644 T DK93916644 T DK 93916644T DK 93916644 T DK93916644 T DK 93916644T DK 0646016 T3 DK0646016 T3 DK 0646016T3
Authority
DK
Denmark
Prior art keywords
treatment
myasthenia gravis
peptides
amino acid
synthetic peptides
Prior art date
Application number
DK93916644T
Other languages
English (en)
Inventor
Michael Sela
Edna Mozes
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK0646016T3 publication Critical patent/DK0646016T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK93916644T 1992-06-18 1993-06-18 Syntetiske peptider til behandlling af myasthenia gravis DK0646016T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90039392A 1992-06-18 1992-06-18
PCT/US1993/005906 WO1994000148A1 (en) 1992-06-18 1993-06-18 Synthetic peptides for the treatment of myasthenia gravis

Publications (1)

Publication Number Publication Date
DK0646016T3 true DK0646016T3 (da) 2000-03-20

Family

ID=25412446

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93916644T DK0646016T3 (da) 1992-06-18 1993-06-18 Syntetiske peptider til behandlling af myasthenia gravis

Country Status (11)

Country Link
EP (1) EP0646016B1 (da)
JP (1) JP3996635B2 (da)
AT (1) ATE183652T1 (da)
AU (1) AU678372B2 (da)
CA (1) CA2138258C (da)
DE (1) DE69326145T2 (da)
DK (1) DK0646016T3 (da)
ES (1) ES2139667T3 (da)
GR (1) GR3031371T3 (da)
IL (3) IL122445A (da)
WO (1) WO1994000148A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066621A (en) * 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
EP1037663A2 (en) 1997-12-16 2000-09-27 Regents Of The University Of Minnesota Methods to treat undesirable immune responses
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
WO2022260579A2 (en) 2021-06-07 2022-12-15 Toleranzia Ab Fusion protein in myasthenia gravis
WO2024206202A1 (en) * 2023-03-24 2024-10-03 Cour Pharmaceuticals Development Company Inc. Tolerizing immune modifying nanoparticles for myasthenia gravis treatment

Also Published As

Publication number Publication date
IL122445A0 (en) 1998-06-15
IL106065A0 (en) 1993-10-20
JP3996635B2 (ja) 2007-10-24
ES2139667T3 (es) 2000-02-16
EP0646016A4 (en) 1995-07-12
EP0646016A1 (en) 1995-04-05
DE69326145T2 (de) 2000-04-27
WO1994000148A1 (en) 1994-01-06
AU678372B2 (en) 1997-05-29
IL122445A (en) 2000-08-31
CA2138258C (en) 2003-08-19
DE69326145D1 (de) 1999-09-30
EP0646016B1 (en) 1999-08-25
GR3031371T3 (en) 2000-01-31
JPH07508521A (ja) 1995-09-21
ATE183652T1 (de) 1999-09-15
AU4642993A (en) 1994-01-24
CA2138258A1 (en) 1994-01-06
IL106065A (en) 1999-10-28

Similar Documents

Publication Publication Date Title
DE68929256D1 (de) Humaner Rezeptor Fc(gamma)RIII
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
ATE336511T1 (de) Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren
NL194828B (nl) Somatostatinepeptiden, alsmede dergelijke somatostatinepeptiden bevattende farmaceutische preparaten.
DK1210430T3 (da) MUC-1-afledte peptider
NO873699D0 (no) Polypeptid som er egnet til dempning, behandling og diagnosering av autoimmune lidelser saasom leddbetennelser.
DK0820303T3 (da) p277 peptidanaloger og farmaceutiske sammensætninger, der omfatter dem, til behandling eller diagnosticering af diabetes
HUP9901688A2 (hu) A diabétesz kezelésére szolgáló, humán hősokk protein 60-ból származó új peptidek, készítmények, eljárások és kitek
DK1025849T3 (da) Fremgangsmåder til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-antigener
GR3031371T3 (en) Synthetic peptides for the treatment of myasthenia gravis.
IL122443A0 (en) Synthetic peptides and pharmaceutical compositions comprising them
DE3887053D1 (de) Stlv-iii-verwandte polypeptide, diagnosesysteme und testmethoden.
DK0614910T3 (da) Renset form af streptograminer, dens fremstilling og farmaceutiske præparater indeholdende denne form
ES2142317T3 (es) Polipeptidos de proteinas s y uso de los mismos.
ES2152285T3 (es) Preparacion farmaceutica basada en la proteina celular clara cc10 y su uso como medicamento y en diagnostico.
ATE390440T1 (de) Neuroaktive peptide
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
ATE98962T1 (de) Menschliche rhinoviruspeptide.
DK291089A (da) Kondenserede diazepinoner, fremgangsmaade til fremstilling deraf og laegemidler med indhold af saadanne forbindelser
NO900255L (no) Peptider med t-cellehjelperaktivitet.
DE69012624D1 (de) Reines Histon H1 zur therapeutischen Verwendung.
IT8663238V0 (it) Coperchio-sigillo preferibilmente per flaconi o similari ad uso farmaceutico.